Latest Interviews

Regeneron CEO Dr. Leonard Schleifer on Science-Driven Success

Dr. Leonard Schleifer, John Waldron

Founded in 1988 by MD-PhDs Leonard Schleifer and George Yancopoulos, Regeneron rejects top-down target selection to pursue science-driven therapeutics, enduring two decades of losses before achieving profitability in 2011. The company currently employs 15,000 people and markets Dupixent as its flagship treatment for diverse allergic conditions while leveraging genomic data from 3 million individuals to advance research in areas like obesity and cancer. Under Schleifer's unique leadership style that eschews quarterly earnings guidance, Regeneron is expanding its genetic sequencing efforts to 50 million people and integrating AI to refine diagnostic precision without compromising its "do well by doing good" ethical mandate.